Loading stock data…
$16.64-0.70 (-4.04%)
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.38M↑ | $3.23M↑ | $1.87M↑ | $1.58M↓ | $1.60M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$28.90M↓ | -$22.71M↓ | -$17.38M↑ | -$18.20M↑ | -$20.96M |
| Net Income | -$24.14M↓ | -$18.32M↓ | -$15.14M↑ | -$15.53M↑ | -$18.07M |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-11...